Long-Acting Intelligence

The living market intelligence system for Long-Acting Injectables.

Vectora structures the whole LAI ecosystem into one source: every company, drug, candidate and technology, ready to explore, monitor and build on.

Request access Coverage & method

The landscape today

Long-acting injectables were never given a scope of their own.

So you rebuild it by hand, every time. Vectora maintains it: long-acting injectables as a field of their own, scoped, de-duplicated, and updated as the field moves. So you can put real questions to it, not reassemble it.

The only structured, queryable map of the Long-Acting Injectables landscape.

Coverage & grain

One ecosystem, modeled two ways.

Every company, marketed drug, clinical candidate, trademark, proprietary delivery technology, target and indication in the LAI landscape: defined, curated and resolved into one queryable ontology.

Assets: map the field

Every molecule, marketed and in the pipeline.

Each asset is a molecule × delivery technology × developer. Size the landscape and segment it by phase, technology, target or modality.

Products by market: compare what’s live

Every brand, by regulatory authority.

Each product is a brand × authority. Read the real regulatory profile: FDA against EMA, label by label.

The dimensions you can cross

Delivery technology

MicrosphereNanocrystalIn-situ depotImplantLiposomeOil depotProdrug / esterMatrix materialPEGylationLipidationAlbumin-bindingFc-fusion

Molecule

API classModalityTargetRouteLocal vs systemic effectMW / logP / PSA

Clinical

Therapeutic areaIndicationDevelopment phaseDuration of actionDosing interval

Regulatory: FDA & EMA

Approval by authorityBoxed warningCold chainStorageInjection sitesVolumesStrengthsExcipients

Every dimension shows how completely it is documented across the scope, so you always know how complete a given view is.

One platform, three products

Explore, monitor, produce.

One dataset feeds all three products, each unlocked for your organization as it becomes available.

Available

Atlas

Explore the landscape. Scope a population, compare molecules or products, read FDA against EMA in one view.

Coming

Inbox

A periodic brief of LAI events, filtered to the field: readouts, approvals, deals.

Planned

Studio

Briefs and reports generated on demand, each claim traceable to its source.

Atlas explores · Inbox monitors · Studio produces.

Atlas · Available

Explore the landscape from every angle.

Filter the landscape to the assets you care about, then read it through a lens: a sortable table, a competitive landscape, market trends over decades, a positioning map that exposes white space, and a side-by-side comparison across brands and markets.

Curated, not scraped. Every value is defined and resolved to one LAI ontology; where an official label exists, regulatory facts link straight to it on the FDA or EMA site.

Market growth by therapeutic area over time — **Market growth by therapeutic area**, 1952 to today.

Companies ranked by number of LAI assets, scoped to central nervous system — **Who leads a segment.** Companies ranked by LAI assets, here scoped to the central-nervous-system field.

Assets plotted by molecular weight against polar surface area, colored by delivery technology — **Position map.** Assets by molecular weight against polar surface area, colored by delivery technology.

Delivery-technology families by route, heatmap — **Delivery-technology families × route.** Dark cells are market gaps.

API class by physical release family, heatmap shaded by market share — **API class × release family**, shaded by market share.

Duration-of-action mix, 2010 versus 2024 — **Duration-of-action mix**, 2010 vs 2024.

Atlas Compare view: four brands side by side, FDA and EMA labels with divergences highlighted — **Compare.** Several brands side by side, FDA against EMA, divergences highlighted (here, the same brand is Otsuka on FDA and Lundbeck on EMA).

For your team

Built for the questions each team asks.

The same dataset, read through the lens of each role.

Business Development

“Who competes directly in Phase 3 schizophrenia LAIs, and who develops them?”

Competitive Intelligence

“Are new LAIs trending toward longer intervals, and toward subcutaneous delivery?”

Medical Affairs

“Which LAIs reach a six-month dosing interval, and in which indications?”

Regulatory

“For this brand, what differs between the FDA and the EMA label?”

Marketing

“How many approved LAI products need cold-chain storage, and in what presentations?”

R&D / Strategy

“Where are the white spaces: which technology × therapeutic-area crossings have no asset yet?”

The analyst behind Vectora

Frank Issartel, PharmD

Eleven years in pharmaceutical competitive intelligence.

Vectora encodes that domain work into the dataset itself: the scope, the ontology, the delivery-technology taxonomy. In a specialized field, the analysis is only as strong as the domain knowledge behind it.

You work directly with the analyst who builds and maintains the dataset, not an account manager relaying your questions.